The phase 1 study, which is currently recruiting, includes a 4-week screening period, a 52-week treatment period, and a 4-year long-term extension to continue to test the effects of HG202.:
Source: Neurology Read More
First-Ever CRISPR/Cas13-RNA Editing Therapy to be Tested in Phase 1 Study of Age-Related Macular Degeneration
Related Posts
<![CDATA[Indirect Comparison Analysis of Head-to-Head
Migraine Trials Suggests Early Efficacy Advantage With Atogepant
Over Erenumab ]]>
<![CDATA[Indirect Comparison Analysis of Head-to-Head Migraine Trials Suggests Early Efficacy Advantage With Atogepant Over Erenumab ]]>
